E85.81

Clinical Causes: Clonal proliferation of plasma cells producing abnormal light chains Unidentified factors leading to abnormal plasma cell growth Genetic mutations that may predispose to plasma cell abnormalities

Key Symptoms: Fatigue and weakness Swelling, especially in the legs or ankles Unexplained weight loss Shortness of breath or difficulty breathing Numbness or tingling sensations in the hands or feet Skin changes such as easy bruising or purpura Nausea or loss of appetite Enlargement of the tongue or other tissues

Diagnosis Path: Diagnosing AL amyloidosis involves a combination of blood and urine tests to detect abnormal light chains, tissue biopsies to identify amyloid deposits, and imaging studies to assess organ involvement. Blood tests may include serum free light chain analysis, immunofixation, and complete blood counts. Tissue samples, often obtained from the affected organ or from abdominal fat, are examined under a microscope stained with special dyes to confirm the presence of amyloid. Additional imaging techniques like echocardiograms or MRI can evaluate heart and organ function.

Treatment Protocols: Treatment strategies aim to reduce the production of abnormal light chains and manage organ damage. Common approaches include chemotherapy regimens similar to those used in multiple myeloma, targeted therapies, and possibly stem cell transplants. Supportive care for affected organs, such as diuretics for heart failure or medications for nerve pain, may also be necessary. Regular monitoring is essential to assess response to treatment and adjust therapy as needed.